

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-9 (Canceled)

10. (Currently amended) A method of treating ~~or inhibiting~~ persistent allergic rhinitis comprising administering an effective amount of Levocetirizine or a pharmaceutically acceptable salt thereof to a patient in need of such treatment, where the Levocetirizine or a pharmaceutically acceptable salt thereof is administered in a daily dosage of from about 0.0005 mg to about 2 mg per kg of body weight per patient.

11-21. (Canceled)

22. (New) The method according to claim 10 where the Levocetirizine or a pharmaceutically acceptable salt thereof is administered in a daily dosage of from about 0.005 mg to about 1 mg per kg of body weight per patient.

23. (New) The method according to claim 10 where the Levocetirizine or a pharmaceutically acceptable salt thereof is administered in a daily dosage of about 0.5 mg per kg of body weight per patient.

24. (New) The method according to claim 10 where the Levocetirizine or a pharmaceutically acceptable salt thereof is administered via spray inhalation, aerosol, or topically.

25. (New) The method according to claim 10 where the Levocetirizine or a pharmaceutically acceptable salt thereof is administered orally.

26. (New) The method according to claim 10 where the daily dosage of Levocetirizine or a pharmaceutically acceptable salt thereof is split among 2-5 dosages administered per day.

27. (New) The method according to claim 10 where the daily dosage of Levocetirizine or a pharmaceutically acceptable salt thereof is split between 2 dosages administered per day.

28. (New) The method according to claim 10, wherein the daily dosage is administered in a single dose.

29. (New) The method according to claim 10 where the Levocetirizine or a pharmaceutically acceptable salt thereof is administered during a period equal to or more than 3 months.